4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2016,
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Voir le projet
30
Participants partenaires
TERMINÉ
New drugs targeting influenza virus polymerase (FLU-PHARM)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,
The 2009 H1N1 pandemic and the ongoing threat of highly pathogenic H5N1 strains have focused attention worldwide on the urgent need for effective anti-influenza drug options when the public is not protected by vaccination. The need is pressing since several circulating strains are resistant to currently stock-piled anti-neuraminidase drugs. In this project, we will exploit our recent advances in t ...
Voir le projet
12
Participants partenaires
TERMINÉ
Novel anti-inflammatory compounds for autoimmune diseases (KINACEPT)
Date du début: 1 déc. 2008, Date de fin: 30 nov. 2010,
"The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis. In addition ...
Voir le projet
10
Participants partenaires
TERMINÉ
Small Molecule Inhibitors of the Trimeric Influenza Virus Polymerase Complex (FLUINHIBIT)
Date du début: 1 avr. 2008, Date de fin: 31 mars 2010,
"The clock is counting down to the next influenza pandemic. Since 1997, the avian influenza virus strain H5N1 has infected over 250 people worldwide with a fatality rate of ~60%, although so far without sustained human-to-human transmission. In view of the very few efficacious drugs against influenza virus infections and the time it takes to develop a matching vaccine, there is an unmet worldwide ...
Voir le projet